PET scan to check treatment response in advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that can't be removed by surgery.
- You are between 18 and 75 years old.
- You are willing to follow the study procedures and attend all visits.
- You do not have serious heart, lung, kidney, or other health issues that could make the scan unsafe.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You do not have a bowel perforation or complete blockage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to look at diseases like cancer. It aims to see if this new imaging method can help doctors find or monitor disease better. This could be helpful for people with confirmed or suspected cancer or other conditions.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
This trial studies how well a special imaging test (68Ga-FAPI PET/MRI) can detect and evaluate hepatocellular carcinoma (HCC), a type of liver cancer. It may help doctors confirm diagnosis and plan next steps by seeing how the cancer takes up the tracer.
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.